Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Other Accumulated Expenses (2021 - 2024)

Historic Other Accumulated Expenses for Universe Pharmaceuticals (UPC) over the last 5 years, with Q3 2025 value amounting to $856.6 billion.

  • Universe Pharmaceuticals' Other Accumulated Expenses fell 3238.75% to $856.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $856.6 billion, marking a year-over-year decrease of 3238.75%. This contributed to the annual value of $856.6 billion for FY2025, which is 3238.75% down from last year.
  • Universe Pharmaceuticals' Other Accumulated Expenses amounted to $856.6 billion in Q3 2025, which was down 3238.75% from $1266.9 billion recorded in Q3 2024.
  • In the past 5 years, Universe Pharmaceuticals' Other Accumulated Expenses ranged from a high of $1266.9 billion in Q3 2024 and a low of $52263.0 during Q3 2022
  • Over the past 5 years, Universe Pharmaceuticals' median Other Accumulated Expenses value was $74.0 million (recorded in 2023), while the average stood at $424.7 billion.
  • As far as peak fluctuations go, Universe Pharmaceuticals' Other Accumulated Expenses tumbled by 8823.75% in 2022, and later skyrocketed by 171269371.6% in 2024.
  • Universe Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $444319.0 in 2021, then tumbled by 88.24% to $52263.0 in 2022, then soared by 141426.51% to $74.0 million in 2023, then soared by 1712693.72% to $1266.9 billion in 2024, then tumbled by 32.39% to $856.6 billion in 2025.
  • Its Other Accumulated Expenses stands at $856.6 billion for Q3 2025, versus $1266.9 billion for Q3 2024 and $74.0 million for Q3 2023.